Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.52 |
| ▸ | PRKCA | P17252 | 2/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508259 | 0.86 | MAOB (0.57) | ALDH1A1FFAR1ALOX5MAOBNR4A1 | |
| SCHEMBL8770978 | 0.86 | MAOB (0.57) | ALDH1A1FFAR1ALOX5MAOBNR4A1 | |
| SCHEMBL8770913 | 0.86 | KMT2A (0.57) | LMNAL3MBTL1NR1H4ALDH1A1FFAR1 | |
| SCHEMBL231089 | 0.85 | LMNA (0.56) | LMNAL3MBTL1NR1H4ALDH1A1FFAR1 | |
| SCHEMBL1508528 | 0.85 | FFAR1 (0.62) | LMNAL3MBTL1FFAR1MAOB | |
| SCHEMBL435055 | 0.83 | FFAR1 (0.57) | LMNAL3MBTL1NR1H4ALDH1A1FFAR1 | |
| SCHEMBL435054 | 0.83 | FFAR1 (0.57) | LMNAL3MBTL1NR1H4ALDH1A1FFAR1 | |
| SCHEMBL8771189 | 0.83 | FFAR1 (0.63) | LMNAFFAR1ALOX5MAOBNR4A1 | |
| SCHEMBL10317574 | 0.83 | FFAR1 (0.63) | LMNAFFAR1ALOX5MAOBNR4A1 | |
| SCHEMBL8770928 | 0.83 | FFAR1 (0.51) | FFAR1PRKCAPRKCDALOX5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590930-B1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| EP-2590930-B1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| EP-2590930-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004270-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004270-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-0451668-B1 | Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates | CHISSO CORP (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5202457-A | Enzyme catalyzed transesterification, resolution of optical active alkyl 3-aryl-3-hydroxypropionate | CHISSO CORPORATION (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0451668-A2 | Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof | CHISSO CORPORATION (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | REN, PKD1, AKR1C3 | LMNA 1675/4885L3MBTL1 3957/4885NR1H4 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.